This is a two-party negotiation between a pharmaceutical company and a government agency to decide if a new medication will be put on the reimbursement list. The pharmaceutical company has a valuable new product, the government has semi-monopolistic power over whether (or not) drugs are listed.

This is a two-party negotiation between a pharmaceutical company and a government agency to decide if a new medication will be put on the reimbursement list. The pharmaceutical company has a valuable new product, the government has semi-monopolistic power over whether (or not) drugs are listed.

The Lundbeck case study describes the initial public offering (IPO) that the company made in the summer of 1999.

Business has traditionally enjoyed a pre-eminent position in the Swiss political economy. This case looks at political conflicts over chemicals and biotechnology regulation and Swiss entry into the European Economic Area, showing how the growing environmentalist movements have challenged this position and that important changes in the Swiss political economy may be imminent.